RAPT Therapeutics Inc
RAPT57.690USD
+0.010+0.02%
終値 02/06, 16:00（ET）15分遅れの株価
972.39M時価総額
損失額直近12ヶ月PER
詳細情報 RAPT Therapeutics Inc 企業名
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.
RAPT Therapeutics Incの企業情報
企業コードRAPT
会社名RAPT Therapeutics Inc
上場日Oct 31, 2019
最高経営責任者「CEO」Wong (Brian)
従業員数68
証券種類Ordinary Share
決算期末Oct 31
本社所在地561 Eccles Ave
都市SOUTH SAN FRANCISCO
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号94080
電話番号16504899000
ウェブサイトhttps://rapt.com/
企業コードRAPT
上場日Oct 31, 2019
最高経営責任者「CEO」Wong (Brian)
RAPT Therapeutics Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
4.96K
+4956.00%
Dr. Michael F. Giordano, M.D.
Dr. Michael F. Giordano, M.D.
Independent Director
Independent Director
4.96K
+4956.00%
Ms. Linda Kozick
Ms. Linda Kozick
Independent Director
Independent Director
4.96K
+4956.00%
Ms. Lori Lyons-Williams
Ms. Lori Lyons-Williams
Independent Chairman of the Board
Independent Chairman of the Board
4.96K
+4956.00%
Dr. William (Bill) Ho, M.D., Ph.D.
Dr. William (Bill) Ho, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Brian Wong, M.D., Ph.D.
Dr. Brian Wong, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Rodney K. B. Young
Mr. Rodney K. B. Young
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Dirk Brockstedt, Ph.D.
Dr. Dirk Brockstedt, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Scott N. Braunstein, M.D.
Dr. Scott N. Braunstein, M.D.
Independent Director
Independent Director
--
--
Dr. Ashley Dombkowski, Ph.D.
Dr. Ashley Dombkowski, Ph.D.
Independent Director
Independent Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
4.96K
+4956.00%
Dr. Michael F. Giordano, M.D.
Dr. Michael F. Giordano, M.D.
Independent Director
Independent Director
4.96K
+4956.00%
Ms. Linda Kozick
Ms. Linda Kozick
Independent Director
Independent Director
4.96K
+4956.00%
Ms. Lori Lyons-Williams
Ms. Lori Lyons-Williams
Independent Chairman of the Board
Independent Chairman of the Board
4.96K
+4956.00%
Dr. William (Bill) Ho, M.D., Ph.D.
Dr. William (Bill) Ho, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Brian Wong, M.D., Ph.D.
Dr. Brian Wong, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
収益内訳
会社から関連データがまだ開示されていません。
会社から関連データがまだ開示されていません。
事業別
地域別
会社から関連データがまだ開示されていません。
株主
更新時刻: Mon, Nov 17
更新時刻: Mon, Nov 17
株主統計
種類
株主統計
株主統計
比率
Medicxi Ventures (UK) LLP
9.65%
Forbion Capital Partners
6.33%
TCG Crossover Management, LLC
5.65%
Foresite Capital Management, LLC
5.40%
RTW Investments L.P.
5.08%
他の
67.90%
株主統計
株主統計
比率
Medicxi Ventures (UK) LLP
9.65%
Forbion Capital Partners
6.33%
TCG Crossover Management, LLC
5.65%
Foresite Capital Management, LLC
5.40%
RTW Investments L.P.
5.08%
他の
67.90%
種類
株主統計
比率
Investment Advisor
17.25%
Venture Capital
16.59%
Hedge Fund
11.52%
Private Equity
9.78%
Investment Advisor/Hedge Fund
9.36%
Individual Investor
0.34%
Research Firm
0.31%
Sovereign Wealth Fund
0.04%
他の
34.79%
機関投資家保有株
更新時刻: Thu, Jan 1
更新時刻: Thu, Jan 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
289
18.74M
64.73%
+113.56K
2025Q3
290
16.78M
61.62%
-1.23M
2025Q2
295
16.40M
99.19%
-1.13M
2025Q1
309
29.14M
109.47%
+11.54M
2024Q4
309
140.52M
106.54%
+100.36M
2024Q3
304
31.22M
87.82%
-13.95M
2024Q2
305
33.18M
93.85%
-9.52M
2024Q1
295
33.76M
95.60%
-5.47M
2023Q4
282
36.46M
106.02%
-3.53M
2023Q3
281
36.40M
105.98%
-3.26M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Medicxi Ventures (UK) LLP
2.79M
10.08%
--
--
Sep 30, 2025
Forbion Capital Partners
1.83M
6.62%
+1.49M
+432.58%
Oct 23, 2025
TCG Crossover Management, LLC
1.64M
5.9%
--
--
Sep 30, 2025
Foresite Capital Management, LLC
1.56M
5.64%
--
--
Sep 30, 2025
RTW Investments L.P.
1.47M
5.31%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
696.19K
2.51%
-183.86K
-20.89%
Sep 30, 2025
OrbiMed Advisors, LLC
1.09M
3.92%
-555.29K
-33.82%
Sep 30, 2025
Boone Capital Management LLC
782.46K
2.82%
+782.46K
--
Sep 30, 2025
Deep Track Capital LP
751.42K
2.71%
--
--
Sep 30, 2025
Nantahala Capital Management, LLC
623.28K
2.25%
-328.33K
-34.50%
Sep 30, 2025
詳細を見る
関連ETF
更新時刻: Tue, Dec 2
更新時刻: Tue, Dec 2
銘柄名
比率
Invesco Dorsey Wright SmallCap Momentum ETF
0.56%
Avantis US Small Cap Equity ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Schwab U.S. Broad Market ETF
0%
Blueprint Chesapeake Multi-Asset Trend ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
iShares Russell 3000 ETF
0%
Pacer WealthShield ETF
0%
T Rowe Price Small-Mid Cap ETF
0%
詳細を見る
Invesco Dorsey Wright SmallCap Momentum ETF
比率0.56%
Avantis US Small Cap Equity ETF
比率0.02%
Invesco RAFI US 1500 Small-Mid ETF
比率0.01%
Schwab U.S. Broad Market ETF
比率0%
Blueprint Chesapeake Multi-Asset Trend ETF
比率0%
Virtus LifeSci Biotech Clinical Trials ETF
比率0%
DFA Dimensional US Core Equity Market ETF
比率0%
iShares Russell 3000 ETF
比率0%
Pacer WealthShield ETF
比率0%
T Rowe Price Small-Mid Cap ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
配当落ち日
種類
比率
Jun 13, 2025
Merger
8→1
日付
配当落ち日
種類
比率
Jun 13, 2025
Merger
8→1
